Search for new treatments intensifies for triple-negative breast cancer.
Brower
Vicki
V
D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D019496:Cancer Vaccines / Q000494:pharmacology* / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000494:pharmacology; D066246:ErbB Receptors / Q000187:drug effects; D005260:Female; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D018396:Mucin-1 / Q000187:drug effects; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors; D010446:Peptide Fragments / Q000187:drug effects; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D011379:Prognosis; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D011980:Receptors, Progesterone / Q000378:metabolism
D020533:Angiogenesis Inhibitors; D000951:Antigens, Neoplasm; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; D019496:Cancer Vaccines; D004791:Enzyme Inhibitors; D066246:ErbB Receptors; D018396:Mucin-1; D009363:Neoplasm Proteins; D010446:Peptide Fragments; D000067856:Poly(ADP-ribose) Polymerase Inhibitors; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C072013:MAGEA3 protein, human; C520326:MUC-1 protein, human (950-958); C512478:EGFR protein, human; C508053:ERBB2 protein, human